Compare International Business Machines Corp (IBM) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
International Business Machines Corp vs Medpace Holdings Inc — how do they compare? International Business Machines Corp trades at $227.13 (market cap $213.50B), while Medpace Holdings Inc trades at $612.05 (market cap $16.82B). The key difference: International Business Machines Corp is far larger — about 12.7× Medpace Holdings Inc's market cap, and International Business Machines Corp pays a 2.98% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold International Business Machines Corp for 88 Days and Medpace Holdings Inc for 14 Days on average.
| IBM | MEDP | |
|---|---|---|
Market Cap | $213.50B | $16.82B |
Volume | 8,908,687 | 223,093 |
Sector | Technology | Health |
52-Week High | $329.23 | $630.19 |
52-Week Low | $205.77 | $393.42 |
Typical Hold Time | 88 Days | 14 Days |
Enterprise Value | $270.64B | $16.44B |
Dividend Yield | 2.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IBM's stock trades at $226.61, up 2.77% today, with a bearish technical signal but strong fundamentals including a 15.52% net income margin and consistent earnings beats. Recent news highlights the launch of self-hosted deployment for its Bob AI platform, boosting AI consulting prospects. Revenue grew to $67.54B in 2025, though cash flow turned negative due to heavy investing.
Outlook is mixed: analyst consensus targets $255.50 with 47% buy ratings, but technical weakness and a high P/E of 20.13 suggest caution. Risks include cyclical demand swings and debt levels, while AI initiatives offer growth potential. Investors should weigh solid profitability against near-term volatility.
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About International Business Machines Corp
International Business Machines Corporation (IBM) provides computer solutions. The Company offers application, technology consulting and support, process design and operations, cloud, digital workplace, and network services, as well as business resiliency, strategy, and design solutions. IBM serves clients worldwide.
Read more on IBM →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
